Rheumatoid arthritis and periodontitis: Biological links and the emergence of dual purpose therapies

Indian Journal of Dental Research

Volumn 20, Issue 1, 2009, Pages 86-90

  Modi, Depinder Kaur ^a   Chopra, Vipinder Singh ^a   Bhau, Usha ^b  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b J and K Health Services   (India)

Author keywords

Biological linkages; Periodontitis; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; AUTACOID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TETRACYCLINE DERIVATIVE;

ANIMAL; HUMAN; PATHOPHYSIOLOGY; PERIODONTITIS; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; PERIODONTITIS; TETRACYCLINES;

EID: 64249170084     PISSN: 09709290     EISSN: 1998359X     Source Type: Journal    
DOI: 10.4103/0970-9290.49070     Document Type: Review

References (41)

1. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-6.
2. Woolley DE, Crossley MJ, Evanson JM. Collagenases at sites of cartilage erosion in the rheumatoid joint. Arthritis Rheum 1977;20:1231-9.
3. Haynes DR, Crotti TN, Capone M, Bain GI, Atkin GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001;40:623-30.
4. Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/ pannus junction in patients with rheumatoid arthritis: Implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992;31:653-61.
5. Papapanau PN. Periodontal disease: Epidemiology. Ann Periodontol 1996;1:1-36.
6. Takashiba S, Naruishi K, Murayama Y. Perspective of cytokine regulation for periodontal treatment: Fibroblast biology. J Periodont 2003;74:103- 10.
7. Mercado F, Marshall RI, Klestov AC, Bartold PM. Is there a relationship between rheumatoid arthritis and periodontal disease? J Clin Periodontol 2000;27:267-72.
8. Mercado FB, Marshall RI, Klestov AC, Bartold PM. Relationship between rheumatoid arthritis and periodontitis. J Periodontol 2001;72:779-87.
9. Slots J. Systemic antibiotics in periodontics. J Periodont 1996;67:831-8.
10. Ogrendik M, Kokino S, Ozdemir F, Bird PS, Hamlet S. Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis. MedGenMed 2005;7:2-10.
11. Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G. Hypothesis: The humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation 2004;28:311-8.
12. Schett G, Redlich K, Xu Q, Bizan P, Gröger M, Tohidast-Akrad M, et al. Enhanced expression of heatshock protein 70 (hsp 70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue: Differential regulation of expression and hsf1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and anti-inflammatory drugs. J Clin Invest 1998;102:302-11.
13. Marotte H, Farge P, Gaudin P, Alexandre C, Mougin B, Miossec P. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitopes. Ann Rheum Dis 2006;65:905-9.
14. Havemose-Poulsen A, Sørensen LK, Stoltze K, Bendtzen K, Holmstrup P. Cytokine profiles in peripheral blood and whole blood cell cultures associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. J Periodontol 2005;76:2276-85.
15. Havemose-Poulsen A, Sørensen LK, Bendtzen K, Holmstrup P. Polymorphism within the IL-1 gene cluster: Effects on cytokine profiles in peripheral blood and whole blood cell cultures of patients with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. J Periodontol 2007;78:475-92.
16. Rammamurthy NS, Greenwald RA, Celiker MY, Shi EY. Experimental arthritis in rats induces biomarkers of periodontitis which are ameliorated by gene therapy with tissue inhibitor of matrix metalloproteinases. J Periodontol 2005;76:229-33.
17. Golub LM, Rammamurthy NS, McNamara TF, Gomes B, Wolff M, Casino A, et al. Tetracyclins inhibit tissue collagenase activity: A new mechanism in the treatment of periodontal disease. J Periodontol Res 1984;19:651-5.
18. Rifkin BR, Vermillo AT, Golub LM. Blocking periodontal disease progression by inhibiting tissue destructive enzymes: A potential therapeutic role for tetracyclins and their chemically modified analogues. J Periodontol 1993;64:819-23.
19. Choi DH, Moon IS, Choi BK, Park JW, Kim YS, Choi SH, et al. Effects of sub-antimicrobial dose of doxycycline therapy on cervicular fluid MMP-8 and gingival tissue MMP-9, TIMP-1 and IL-6 levels in chronic periodontitis. J Periodontol Res 2004;39:20-6.
20. Fiedorczyk M, Klimiuk PA, Sierakowski S, Gindzienska-Sieskiewicz E, Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J Rheumatol 2006;33:1523-9.
21. Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Meta analysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol 2003;30:2112-22.
22. Sorsa T, Tjaderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, et al. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 2006;38:306-21.
23. Ciancio S, Ashley R. Safety and efficacy of sub-antimicrobial dose of doxycycline therapy in patients with adult periodontitis. Adv Dent Res 1998;12:27-31.
24. Zubery Y, Dunstan CR, Stony BM, Kesavalu L, Ebersole JL, Holt SC, et al. Bone resorption caused by three periodontolal pathogens in vivo in mice is mediated in part by prostaglandins. Infect Immun 1998;66:4158-62.
25. EL attar TM, Lin HS. Prostaglandins in gingival of patients with periodontal disease. J Periodontol 1981;53:16-20.
26. Salvi GE, Williams RC, Offenbacher S. Nonsteroidal anti-inflammatory drugs as adjuncts in the management of periodontal diseases and peri-implantitis. Curr Opin Periodontol 1997;4:51-8.
27. Pillinger MH, Capodici C, Rosenthal P, Kheterpal N, Hanft S, Philips MR, et al. Mode of action of aspirin-like drugs: Salicylates inhibit erk activation and integrin dependent neutrophil adhesion. Proc Natl Acad Sci USA 1998;95:14540-5.
28. Gunella G, Bardelli C, Spina S, Fresu LG, Viano I, Brunelleschi S. Antiinflammatory drugs and tumor necrosis factor alpha production from monocytes: Role of transcription factor NF-Kappa B and implication for rheumatoid arthritis therapy. Eur J Pharmacol 2004;6:199-208.
29. Breuil V, Euller-Ziegler L. Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 2006;73:349-54.
30. Jarrrtt SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann CE, O.Connor PJ, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006;54:1410-4.
31. Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: Results of a 12-month randomized placebo controlled study. J Periodontol 2005;76:1113-22.
32. Kamma JJ, Nakou M, Mitsis FJ. The clinical and microbiological effects of systemic ornidazole in sites with and without subgingival debridement in early-onset periodontitis patients. J Periodontol 2000;71:1862-73.
33. Ogrendik M, Hakguder A, Keser N. Treatment of rheumatoid arthritis with ornidazole: A randomized double blind, placebo-controlled study. Rheumatology (Oxford) 2006;45:636-7.
34. Golub LM, Soummalainen K, Sorsa T. Host modulation with tetracyclins and their chemically modified analogues. Curr Opin Dent 1992;2:80-90.
35. Sapadin AN, Fleischmajer R. Tetracyclins: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258-65.
36. Holmes SG, Still K, Buttle DJ, Bishop NJ, Grabowski PS. Chemically modified tetracyclins act through multiple mechanisms directly on osteoclast precursors. Bone 2004;35:471-8.
37. D.Agostino P, Ferlazzo V, Milano S, La Rosa M, Di Bella G, Caruso R, et al. Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line. Int Immunopharmacol 2001;1:1765-76.
38. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and OSteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004;83:166-9.
39. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003;15:280-7.
40. Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthrithropathies and osteoarthritis and normal controls. Rheumatology 2003;42:123-34.
41. Rahman MM, Bhattacharya A, Fernandes G. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling. J Lipid Res 2006;47:1739-48.